- Home
- QFIN vs ZYME Comparison
QFIN vs ZYME Comparison
Compare QFIN & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QFIN | ZYME |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | QFIN | ZYME |
|---|---|---|
| Price | $12.33 | $24.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $32.37 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 1.4M | 668.2K |
| Earning Date | 03-17-2026 | 03-02-2026 |
| Dividend Yield | ★ 12.22% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | N/A | $162.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.21 | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $12.60 | $9.03 |
| 52 Week High | $46.18 | $28.49 |
Technical Indicators
Market Signals| Indicator | QFIN | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 28.63 | 52.31 |
| Support Level | N/A | $22.28 |
| Resistance Level | $14.63 | $27.54 |
| Average True Range (ATR) | 0.57 | 1.07 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 0.00 | 49.31 |
Price Performance
Historical ComparisonAbout QFIN Qifu Technology Inc.
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.